Sanofi

Clinical Study Results Medicines, including Rare Diseases

Important

Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country. In the event that the product is described as no longer a Sanofi product, reasons could include that the product was transferred to another company.

This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

Filter by:

And

1248 result(s) found
Generic NameTrade NameCondition(s)Study CodeStudy NameAccess to Study / ProtocolAccess to Results
VALPROATE
Depakine
Bipolar Disorder
L_9524ADOKOTNCT00271258Summary
VALPROATE
Depakine
Epilepsy
L_9557CIVETSummary
VALPROATE
Depakine
Bipolar Disorder
R_8740VALIDNCT00264173Summary
VANDETANIB
Caprelsa
Lung Cancer
D4200C00032ZODIACNCT00312377Tabulated Results
VANDETANIB
Caprelsa
Lung Cancer
D4200C00036ZEAlNCT00418886Tabulated Results
VANDETANIB
Caprelsa
Lung Cancer
D4200C00044NANCT00404924Tabulated Results
VANDETANIB
Caprelsa
Breast Cancer
D4200C00045NAEudraCT: 2005-003591-38Summary Results
VANDETANIB
Caprelsa
Breast Cancer
D4200C00046NANCT00494481Tabulated Results
VANDETANIB
Caprelsa
Colorectal Cancer
D4200C00048NANCT00454116Tabulated Results
VANDETANIB
Caprelsa
Prostate Cancer
D4200C00055NANCT00498797Tabulated Results

References:

* These study results were previously posted on GenzymeClinicalResearch.com
** This link replaces the same summary that was previously posted